Cancer Genomics and Proteomics pp 187-202 | Cite as
Monitoring Methylation and Gene Expression in Cancer
- 1.6k Downloads
Abstract
Identification of patterns of DNA methylation in higher order eukaryotes has become necessary through recognition that disease processes such as cancer can result from abnormal methylation patterns. Abnormal DNA methylation affecting the promoter region of genes can halt their expression, making DNA methylation a marker of gene inactivation. The explosion of studies involving changes in DNA methylation in the last 10 yr, particularly in the study of cancer, are largely the result of two factors: the increasing awareness of the importance of epigenetic silencing in cancer and the improvements in the techniques used to determine changes in DNA methylation. In this chapter, focus is made on the specific methods of how to perform bisulfite modification of DNA and polymerase chain reaction as well as nested methylation specific polymerase chain reaction, and discuss other techniques to evaluate DNA methylation along with the limitations inherent in each process.
Key Words
Bisulfite sequencing CpG island (“C” nucleotide immediately followed by a “G” nucleotide. The “p” in CpG refers to the phosphate group linking the two bases), cytosine epigenetics guanine methylated allele methylation specific PCR (msp) nested methylation primer specific PCR (NMSP), restriction enzyme unmethylated alleleReferences
- 1.Ohtani-Fujita, N., Fujita, T., Aoike, A., Osifchin, N. E., Robbins, P. D., and Sakai, T. (1993) CpG methylation inactivates the promoter activity of the human retinoblastoma tumor-suppressor gene. Oncogene 8, 1063–1067.PubMedGoogle Scholar
- 2.Herman, J. G., Latif, F., Weng, Y., et al. (1994) Silencing of the VHL tumor suppressor gene by DNA methylation in renal carcinoma. Proc. Natl. Acad. Sci. USA 91, 9700–9704.CrossRefPubMedGoogle Scholar
- 3.Merlo, A., Herman, J. G., Mao, L., et al. (1995) 5′ CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med. 1, 686–692.CrossRefPubMedGoogle Scholar
- 4.Frommer, M., McDonald, L. E., Millar, D. S., et al. (1992) A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc. Natl. Acad. Sci. USA 89, 1827–1831.CrossRefPubMedGoogle Scholar
- 5.Herman, J. G., Graff, J. R., Myohanen, S., Nelkin, B. D., and Baylin, S. B. (1996) Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA 93, 9821–9826.CrossRefPubMedGoogle Scholar
- 6.Cameron, E. E., Baylin, S. B., and Herman, J. G. (1999) p15 CpG island methylation in primary acute leukemia is heterogeneous and suggests density as a critical factor for transcriptional silencing. Blood 94, 2445–2451.PubMedGoogle Scholar
- 7.Xiong, Z. and Laird, P. W. (1997) COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res. 25, 2532–2534.CrossRefPubMedGoogle Scholar
- 8.Gonzalgo, M. L. and Jones, P. A. (1997) Rapid quantitation of methylation differences at specific sites using methylation-sensitive single nucleotide primer extension (Ms-SNuPE) Nucleic Acids Res. 25, 2529–2531.CrossRefPubMedGoogle Scholar
- 9.Galm, O., Rountree, M. R., Bachman, K. E., Jair, K. W., Baylin, S. B., and Herman, J. G. (2002) Enzymatic regional methylation assay: a novel method to quantify regional CpG methylation density. Genome Res. 12, 153–157.CrossRefPubMedGoogle Scholar
- 10.Bird, A. P. (1986) CpG-rich islands and the function of DNA methylation. Nature 321, 209–213.CrossRefPubMedGoogle Scholar
- 11.House, M. G., Herman, J. G., Guo, M. Z., et al. (2003) Aberrant hypermethylation of tumor suppressor genes in pancreatic endocrine neoplasms. Ann. Surg. 238, 423–432.PubMedGoogle Scholar